Your browser doesn't support javascript.
loading
Effects of recombinant human interleukin 11 and granulocyte colony stimulating factor in mobilization for autologous peripheral blood stem cell transplantation / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 345-349, 2008.
Artigo em Chinês | WPRIM | ID: wpr-253322
ABSTRACT
This study was aimed to evaluate the effects of recombinant human interleukin 11 (rhIL-11) and recombinant human granulocyte colony stimulating factor (rhG-CSF) in mobilization for autologous peripheral blood stem cell transplantation (APBSCT). 16 patients with non-Hodgkin's lymphoma or acute myeloblastic leukemia were given myelosuppressive chemotherapy, then were mobilized by using rhG-CSF 5 microg/(kg.d) for median 5.5 days and rhIL-11 50 microg/(kg.d) for median 4 days (experimental group) or rhG-CSF 5 microg/(kg.d) alone for median 5.5 days (control group). After mobilizing, the peripheral blood leucocyte and platelet counts, total mononuclear cells, CD34+ cells and CFU-GM counts in PBSC collection, and amount of apheresed platelet transfusion were assayed. The results showed that the peripheral blood leucocyte and platelet counts, total mononuclear cell, CD34+ cell and CFU-GM counts in PBSC collection were no significant difference between two groups (p>0.05). After APBSCT, the median time for neutrophil count>or=0.5x10(9)/L and the median time for platelet count>or=20x10(9)/L were 10.5 and 11.5 days in experimental group, while were 13 and 13 days in control group, respectively. The median amount of apheresed platelet transfusion was 3.5 unit in experimental group and 5 unit in control group. Data were significantly different between two groups (p<0.05). The adverse reactions of mobilization were mild fever, fatigue, symptoms like as common cold, poor appetite, dizziness, muscular soreness in experimental group, but only mild fever in control. These symptoms were well tolerated and overcome with drug withdrawal. It is concluded that the regimen of rhIL-11 in combination with rhG-CSF after myelosuppressive chemotherapy to mobilize PBSC is efficient and safe with rapid hematologic reconstitution and less platelet transfusions after APBSCT were used.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Transplante Autólogo / Linfoma não Hodgkin / Proteínas Recombinantes / Leucemia Mieloide Aguda / Fator Estimulador de Colônias de Granulócitos / Interleucina-11 / Mobilização de Células-Tronco Hematopoéticas / Transplante de Células-Tronco de Sangue Periférico / Métodos Limite: Adolescente / Adulto / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2008 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Transplante Autólogo / Linfoma não Hodgkin / Proteínas Recombinantes / Leucemia Mieloide Aguda / Fator Estimulador de Colônias de Granulócitos / Interleucina-11 / Mobilização de Células-Tronco Hematopoéticas / Transplante de Células-Tronco de Sangue Periférico / Métodos Limite: Adolescente / Adulto / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2008 Tipo de documento: Artigo